<p>enGene Holdings Inc. (NASDAQ:ENGN - 获取免费报告) 的股票在周二交易中上涨了 4.6%。该公司的股价最高达到 9.06 美元，最后交易价为 9.1760 美元。在交易中，共成交了 4,166 股，较平均交易量 403,350 股下降了 99%。该股票之前的收盘价为 8.77 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师最近对 ENGN 股票发表了看法。HC Wainwright 在 12 月 3 日的报告中重申了 “买入” 评级，并设定了 25.00 美元的目标价。瑞银集团将 enGene 的目标价从 4.00 美元上调至 10.00 美元，并在 11 月 12 日的报告中给予该股票 “中性” 评级。Weiss Ratings 在 10 月 14 日的研究报告中重申了 enGene 的 “卖出（d-）” 评级。花旗集团在 11 月 12 日的研究报告中重申了 enGene 的 “市场表现优于大盘” 评级。最后，Raymond James Financial 将 enGene 的评级从 “表现优于大盘” 上调至 “强力买入”，并在 11 月 11 日的报告中设定了 27.00 美元的目标价。一位股票研究分析师给予该股票 “强力买入” 评级，七位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，enGene 目前的平均评级为 “适度买入”，共识目标价为 22.38 美元。</p>
<p><strong>查看我们关于 ENGN 的最新报告</strong></p>
<h2>enGene 股票表现</h2>
<p>该公司的市值为 5.922 亿美元，市盈率为-4.83，贝塔值为-0.28。公司的债务与股本比率为 0.09，流动比率为 10.34，速动比率为 10.34。该股票的 50 日移动平均线为 7.89 美元，200 日移动平均线为 5.79 美元。</p>
<p>enGene (NASDAQ:ENGN - 获取免费报告) 最近在 12 月 22 日发布了季度财报。该公司报告每股收益（EPS）为-0.73 美元，低于共识预期的-0.55 美元，差额为-0.18 美元。整体来看，股票分析师预计 enGene Holdings Inc.在当前财年将发布-1.56 美元的每股收益。</p>
<h2>enGene 的机构交易</h2>
<p>几家对冲基金最近增加或减少了在 ENGN 的持股。Braidwell LP 在第三季度以约 15,479,000 美元的估值收购了 enGene 的新头寸。Adage Capital Partners GP L.L.C.在第一季度将其在 enGene 的持股增加了 2.7%。Adage Capital Partners GP L.L.C.目前拥有 1,571,642 股该公司的股票，估值为 7,041,000 美元，此前在上个季度增持了 41,874 股。MAI Capital Management 在第一季度将其在 enGene 的持股增加了 11.0%。MAI Capital Management 目前拥有 78,067 股该公司的股票，价值 350,000 美元，此前在此期间增持了 7,756 股。Affinity Asset Advisors LLC 在第二季度以约 280,000 美元的估值购买了 enGene 的新头寸。最后，Citadel Advisors LLC 在第三季度将其在 enGene 的持股增加了 153.3%。Citadel Advisors LLC 目前拥有 58,370 股该公司的股票，估值为 399,000 美元，此前在上个季度增持了 35,327 股。机构投资者和对冲基金持有该公司 64.16% 的股票。</p>
<h2>enGene 公司简介</h2>
<p>(获取免费报告)</p>
<p>enGene, Inc 是一家临床阶段的生物制药公司，专注于开发基于基因的肿瘤治疗药物。该公司的核心技术是 EnGene 递送载体（EDV）平台，该平台利用非活性、细菌衍生的微小细胞直接将治疗药物输送到肿瘤细胞。通过将靶向递送与强效药物结合，enGene 旨在提高癌症治疗的精准性和有效性，同时减少非靶向毒性。</p>
<p>通过其 EDV 平台，enGene 已将多个治疗候选药物推进到临床前和临床阶段。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 enGene</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将爆发</li>
<li>埃隆警告 “美国破产”。特朗普的计划在此。</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 enGene 吗？</h2>
<p>在你考虑 enGene 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 enGene 并不在名单上。</p>
<p>虽然 enGene 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ENGN

<p>enGene（纳斯达克代码：ENGN）股价上涨 4.6%，至 9.1760 美元，交易量显著低于平均水平。分析师的评级意见不一，普遍共识为 “适度买入”，目标价为 22.38 美元。该公司专注于基于基因的癌症治疗。近期有机构投资的消息被提及。enGene 报告的季度每股亏损为 0.73 美元，未能达到预期。市值为 5.922 亿美元</p>

<p>enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) shares shot up 4.6% during trading on Tuesday . The company traded as high as $9.06 and last traded at $9.1760. 4,166 shares traded hands during trading, a decline of 99% from the average session volume of 403,350 shares. The stock had previously closed at $8.77.</p>
<div class="lb-trans"><p>enGene Holdings Inc. (NASDAQ:ENGN - 获取免费报告) 的股票在周二交易中上涨了 4.6%。该公司的股价最高达到 9.06 美元，最后交易价为 9.1760 美元。在交易中，共成交了 4,166 股，较平均交易量 403,350 股下降了 99%。该股票之前的收盘价为 8.77 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts have recently weighed in on ENGN shares. HC Wainwright reissued a &#34;buy&#34; rating and set a $25.00 price objective on shares of enGene in a report on Wednesday, December 3rd. UBS Group raised their price objective on shares of enGene from $4.00 to $10.00 and gave the stock a &#34;neutral&#34; rating in a report on Wednesday, November 12th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of enGene in a research report on Tuesday, October 14th. Citigroup reissued a &#34;market outperform&#34; rating on shares of enGene in a research report on Wednesday, November 12th. Finally, Raymond James Financial raised enGene from an &#34;outperform&#34; rating to a &#34;strong-buy&#34; rating and set a $27.00 price objective on the stock in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, enGene presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $22.38.</p>
<div class="lb-trans"><p>几位分析师最近对 ENGN 股票发表了看法。HC Wainwright 在 12 月 3 日的报告中重申了 “买入” 评级，并设定了 25.00 美元的目标价。瑞银集团将 enGene 的目标价从 4.00 美元上调至 10.00 美元，并在 11 月 12 日的报告中给予该股票 “中性” 评级。Weiss Ratings 在 10 月 14 日的研究报告中重申了 enGene 的 “卖出（d-）” 评级。花旗集团在 11 月 12 日的研究报告中重申了 enGene 的 “市场表现优于大盘” 评级。最后，Raymond James Financial 将 enGene 的评级从 “表现优于大盘” 上调至 “强力买入”，并在 11 月 11 日的报告中设定了 27.00 美元的目标价。一位股票研究分析师给予该股票 “强力买入” 评级，七位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，enGene 目前的平均评级为 “适度买入”，共识目标价为 22.38 美元。</p>
</div><p><strong>View Our Latest Report on ENGN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ENGN 的最新报告</strong></p>
</div><h2>enGene Stock Performance</h2>
<div class="lb-trans"><h2>enGene 股票表现</h2>
</div><p>The firm has a market capitalization of $592.20 million, a P/E ratio of -4.83 and a beta of -0.28. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The stock's 50 day moving average is $7.89 and its two-hundred day moving average is $5.79.</p>
<div class="lb-trans"><p>该公司的市值为 5.922 亿美元，市盈率为-4.83，贝塔值为-0.28。公司的债务与股本比率为 0.09，流动比率为 10.34，速动比率为 10.34。该股票的 50 日移动平均线为 7.89 美元，200 日移动平均线为 5.79 美元。</p>
</div><p>enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). As a group, equities analysts anticipate that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>enGene (NASDAQ:ENGN - 获取免费报告) 最近在 12 月 22 日发布了季度财报。该公司报告每股收益（EPS）为-0.73 美元，低于共识预期的-0.55 美元，差额为-0.18 美元。整体来看，股票分析师预计 enGene Holdings Inc.在当前财年将发布-1.56 美元的每股收益。</p>
</div><h2>Institutional Trading of enGene</h2>
<div class="lb-trans"><h2>enGene 的机构交易</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in ENGN. Braidwell LP acquired a new position in shares of enGene in the 3rd quarter valued at approximately $15,479,000. Adage Capital Partners GP L.L.C. lifted its position in enGene by 2.7% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company's stock valued at $7,041,000 after acquiring an additional 41,874 shares in the last quarter. MAI Capital Management boosted its stake in enGene by 11.0% in the 1st quarter. MAI Capital Management now owns 78,067 shares of the company's stock worth $350,000 after purchasing an additional 7,756 shares during the period. Affinity Asset Advisors LLC bought a new position in enGene during the 2nd quarter worth about $280,000. Finally, Citadel Advisors LLC lifted its holdings in shares of enGene by 153.3% in the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company's stock valued at $399,000 after purchasing an additional 35,327 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了在 ENGN 的持股。Braidwell LP 在第三季度以约 15,479,000 美元的估值收购了 enGene 的新头寸。Adage Capital Partners GP L.L.C.在第一季度将其在 enGene 的持股增加了 2.7%。Adage Capital Partners GP L.L.C.目前拥有 1,571,642 股该公司的股票，估值为 7,041,000 美元，此前在上个季度增持了 41,874 股。MAI Capital Management 在第一季度将其在 enGene 的持股增加了 11.0%。MAI Capital Management 目前拥有 78,067 股该公司的股票，价值 350,000 美元，此前在此期间增持了 7,756 股。Affinity Asset Advisors LLC 在第二季度以约 280,000 美元的估值购买了 enGene 的新头寸。最后，Citadel Advisors LLC 在第三季度将其在 enGene 的持股增加了 153.3%。Citadel Advisors LLC 目前拥有 58,370 股该公司的股票，估值为 399,000 美元，此前在上个季度增持了 35,327 股。机构投资者和对冲基金持有该公司 64.16% 的股票。</p>
</div><h2>enGene Company Profile</h2>
<div class="lb-trans"><h2>enGene 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.</p>
<div class="lb-trans"><p>enGene, Inc 是一家临床阶段的生物制药公司，专注于开发基于基因的肿瘤治疗药物。该公司的核心技术是 EnGene 递送载体（EDV）平台，该平台利用非活性、细菌衍生的微小细胞直接将治疗药物输送到肿瘤细胞。通过将靶向递送与强效药物结合，enGene 旨在提高癌症治疗的精准性和有效性，同时减少非靶向毒性。</p>
</div><p>Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.</p>
<div class="lb-trans"><p>通过其 EDV 平台，enGene 已将多个治疗候选药物推进到临床前和临床阶段。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than enGene</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 enGene</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将爆发</li>
<li>埃隆警告 “美国破产”。特朗普的计划在此。</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in enGene Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 enGene 吗？</h2>
</div><p>Before you consider enGene, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 enGene 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 enGene 并不在名单上。</p>
</div><p>While enGene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 enGene 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

enGene（NASDAQ:ENGN）股价上涨 4.6% - 接下来会发生什么？